Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Salmeterol

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    203 result(s) found for: Salmeterol. Displaying page 1 of 11.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-005107-17 Sponsor Protocol Number: 1184.15 Start Date*: 2008-01-28
    Sponsor Name:Boehringer Ingelheim bv
    Full Title: A 24-week (+ 24 week extension), randomized, placebo-controlled (only 1st 12-week period), double–blind, parallel-group, efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhal...
    Medical condition: Moderate to severe COPD
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    9.1 10010953 COPD exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) ES (Completed) FI (Completed) DE (Prematurely Ended) PT (Prematurely Ended) BE (Completed) FR (Completed) SE (Prematurely Ended) DK (Prematurely Ended) LV (Prematurely Ended) HU (Prematurely Ended) LT (Prematurely Ended) EE (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended) AT (Prematurely Ended) SK (Completed)
    Trial results: View results
    EudraCT Number: 2007-005134-36 Sponsor Protocol Number: 1184.14 Start Date*: 2008-01-28
    Sponsor Name:Boehringer Ingelheim bv
    Full Title: A 24-week (+ 24 week extension), randomized, placebo-controlled (only 1st 12-week period), double–blind, parallel-group, efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhal...
    Medical condition: Moderate to severe COPD
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    9.1 10010953 COPD exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) ES (Completed) FI (Completed) PT (Prematurely Ended) DE (Prematurely Ended) BE (Completed) DK (Completed) FR (Completed) SE (Prematurely Ended) IT (Prematurely Ended) LV (Prematurely Ended) GR (Completed) LT (Prematurely Ended) EE (Prematurely Ended) SK (Completed) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002139-33 Sponsor Protocol Number: WADA2013sal Start Date*: 2014-09-26
    Sponsor Name:Bispebjerg University Hospital
    Full Title: Pharmacokinetics of inhaled salmeterol administrated in healthy trained males
    Medical condition: Pharmacokinetics of salmeterol regarding uptake and excretion
    Disease: Version SOC Term Classification Code Term Level
    17.0 10022891 - Investigations 10022891 Investigations SOC
    Population Age: Adults Gender: Male
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004865-10 Sponsor Protocol Number: SFA100062 Start Date*: 2016-12-08
    Sponsor Name:GlaxoSmithKiline Research and Development LTD.
    Full Title: A Randomized, Parallel Group, Double-Blind, Comparative Trial Assessing Lung Function and Other Measures of Asthma Control in Adults and Adolescents, at least 12 Years of Age, with Asthma, Who Have...
    Medical condition: Asthma
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-000735-14 Sponsor Protocol Number: L-A/2017/COM/01 Start Date*: 2018-01-19
    Sponsor Name:Lek-Am Sp. z o.o.
    Full Title: The efficacy and safety of new formulation of combination of fluticasone propionate / salmeterol (125μg / 25μg) in MDI HFA inhaler compared with the reference drug at a dose of 500μg / 50μg in DPI...
    Medical condition: Asthma is a common, chronic respiratory disease affecting 1–18% of the population in different countries. Asthma is characterized by variable symptoms of wheeze, shortness of breath, chest tightnes...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-000207-15 Sponsor Protocol Number: 1184.24 Start Date*: 2008-02-26
    Sponsor Name:Boehringer Ingelheim bv
    Full Title: A randomised, open-label, 4-way crossover study to characterize the pharmacokinetics, safety and efficacy of tiotropium and salmeterol after inhalation of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhal...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-006793-26 Sponsor Protocol Number: 06-03/DPI Salmeterol_50 Start Date*: 2007-09-20
    Sponsor Name:mibe GmbH Arzneimittel
    Full Title: Randomised, double-blind, double-dummy, cross-over trial comparing salmeterol 50 µg b.i.d. via a novel DPI versus salmeterol 50 µg b.i.d. via Diskus in adult patients with persistent asthma
    Medical condition: Adult patients with stable persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049106 Asthma chronic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004966-16 Sponsor Protocol Number: CQVA149A2318 Start Date*: 2013-02-27
    Sponsor Name:Novartis Pharma AG
    Full Title: A 52-week treatment, multi-center, randomized, double-blind, double-dummy, parallel-group, active controlled study to compare the effect of QVA149 (indacaterol maleate / glycopyrronium bromide) wit...
    Medical condition: subjects with moderate to very severe COPD
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10010953 COPD exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) SE (Completed) ES (Completed) AT (Completed) LT (Completed) NL (Completed) CZ (Completed) FI (Completed) DE (Completed) BE (Completed) IS (Completed) IT (Completed) PT (Completed) NO (Completed) PL (Completed) EE (Completed) DK (Completed) BG (Completed) LV (Completed) GR (Completed) GB (Completed) LU (Completed)
    Trial results: View results
    EudraCT Number: 2017-003330-91 Sponsor Protocol Number: BUSAL-II-17-1 Start Date*: 2017-11-29
    Sponsor Name:Laboratoires SMB S.A.
    Full Title: A pharmacokinetic and pharmacodynamic, randomised, single dose, cross-over, partially blinded study to compare the systemic exposure and the efficacy of a fixed-dose combination of Budesonide-Salme...
    Medical condition: Regular Treatment of Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000015470 10003560 Asthma NOS LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2005-003991-39 Sponsor Protocol Number: I-025 Start Date*: 2005-12-08
    Sponsor Name:insaf, Institut für Atemwegsforschung GmbH
    Full Title: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL CROSSOVER TRIAL IN ADULT ASTHMATICS EVALUATING THE EFFECT OF CONCOMITANT TWO WEEKS TREATMENT WITH MONTELUKAST (SINGULAIR™) 10 MG ONCE DAILY OR ...
    Medical condition: Intermittend or mild asthma according to the definition of the Global Initiative ofor Asthma (GINA) guidelines step 1 or step 2 (2004)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003036-23 Sponsor Protocol Number: 19SM5101 Start Date*: 2019-12-02
    Sponsor Name:Imperial College London
    Full Title: Mechanisms of adverse effects of long-acting beta-agonists in asthma
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003638 Atopic asthma LLT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003565 Asthmatic LLT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10015575 Exacerbation of asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-000114-22 Sponsor Protocol Number: CQVA149A2316 Start Date*: 2015-09-02
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 26-week, randomized, double blind, parallel-group multicenter study to assess the efficacy and safety of QVA149 (110/50 μg o.d.) vs tiotropium (18 μg o.d.) + salmeterol/fluticasone propionate FDC...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) EE (Completed) NL (Completed) LV (Completed) LT (Completed) DE (Completed) CZ (Completed) HU (Completed) DK (Completed) SK (Completed) ES (Completed) AT (Completed) PL (Completed) GR (Completed) HR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-002450-30 Sponsor Protocol Number: AcadMed CTU03/05 Start Date*: 2006-07-12
    Sponsor Name:Hull and East Yorkshire Hospitals Trust
    Full Title: An Open label Study to Compare Systemic Side Effects of High Dose Fluticasone/Salmeterol with that of High Dose Ciclesonide /Salmeterol in Symptomatic Asthmatics
    Medical condition: Chronic asthma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004096-19 Sponsor Protocol Number: BALTI Prev 2007 Start Date*: 2007-10-31
    Sponsor Name:Birmingham Heartlands Hospital
    Full Title: Beta Agonist Lung injury Trial - Prevention Study
    Medical condition: This programme of research will examine the role of beta-2 agonist as specific pharmacotherapy to reduce the incidence of Acute Lung Injury (ALI) / Acute Respiratory Distress Syndrome (ARDS) in pat...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-004864-12 Sponsor Protocol Number: SFA103153 Start Date*: 2016-08-03
    Sponsor Name:GlaxoSmithKline
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel Group, 52-Week Comparison of Asthma Control and Measures of Airway Inflammation in Subjects of African Descent Receiving Fluticasone Propionate/Sal...
    Medical condition: Asthma
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-004744-32 Sponsor Protocol Number: 04-SAM-01/BS554 Start Date*: 2006-01-25
    Sponsor Name:Merck Generics UK Ltd.
    Full Title: A CUMULATIVE DOSE RESPONSE STUDY TO EVALUATE THE THERAPEUTIC EQUIVALENCE OF A NEW SALMETEROL INHALATION AEROSOL CONTAINING A REPLACEMENT HFA PROPELLANT IN A PRESSURISED METERED DOSE INHALER AND EX...
    Medical condition: asthma bronchiale
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001581-18 Sponsor Protocol Number: SCO114520 Start Date*: 2012-03-29
    Sponsor Name:GlaxoSmithKline GmbH & Co. KG
    Full Title: Effects of bronchodilatation with salmeterol on the autonomic nervous system
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005620-32 Sponsor Protocol Number: 2006-56-DPI-1 Start Date*: 2009-05-08
    Sponsor Name:HEXAL AG
    Full Title: Efficacy and safety of Salmeterol/Fluticasone DPI HEXAL versus Seretide™ Accuhaler™ in adolescent and adult patients with moderate-to-severe persistent asthma: A 12-week, multicenter, randomized, d...
    Medical condition: moderate-to-severe persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003555 Asthma bronchial LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-001946-10 Sponsor Protocol Number: E-RES/35/13-N08 Start Date*: 2014-08-15
    Sponsor Name:Cipla Ltd.
    Full Title: A randomised, single dose, open label, two-period crossover study evaluating bioequivalence of salmeterol xinafoate HFA pMDI 25μg per actuation manufactured by Cipla Ltd, India (test product) with ...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    17.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004882-10 Sponsor Protocol Number: SAS110099 Start Date*: 2016-08-03
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A study to compare GW815SF HFA MDI with concomitant treatment with salmeterol xinafoate DPI plus fluticasone propionate DPI and to assess long-term safety of GW815SF HFA MDI
    Medical condition: Asthma
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 08:25:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA